Skip to main content
ROSSARI BIOTECH LIMITED logo

ROSSARI BIOTECH LIMITED — Investor Relations & Filings

Ticker · ROSSARI ISIN · INE02A801020 LEI · 335800R7XFRR8ZTHBQ25 BSE.NS Manufacturing
Open in API
Filings indexed 529 across all filing types
Latest filing 2024-01-20 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ROSSARI

About ROSSARI BIOTECH LIMITED

https://www.rossari.com/

Rossari Biotech Limited is a specialty chemicals manufacturer focused on providing sustainable and innovative solutions across diverse sectors. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition. In the HPPC segment, it supplies essential ingredients for detergents, soaps, paints, and water treatment applications. Its textile division offers a comprehensive range of chemicals for the entire textile value chain, including pre-treatment, dyeing, and finishing processes. Additionally, the company provides high-quality feed additives and supplements for the poultry and livestock industries. Driven by robust research and development capabilities, Rossari Biotech emphasizes eco-friendly chemistry and customized formulations to meet specific client requirements. With advanced manufacturing facilities, the company serves a global clientele, maintaining a strong focus on operational excellence.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on January 20, 2024, where the Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023. It includes the financial results themselves, detailed financial tables, and an Independent Auditor's Review Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presence of unaudited quarterly and year-to-date financial results, along with the auditor's limited review report, indicates this is an Interim / Quarterly Report. The document is substantive (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-01-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an intimation notice about an upcoming earnings conference call for Q3 FY24, scheduled for January 23, 2024. It references Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The document includes details about the call timing, dial-in information, and a brief description of the company. It does not contain actual financial results or substantive financial data but rather announces the event where such results will be discussed. The document length is 4578 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement or intimation. However, since it is only an intimation of the earnings conference call and not the transcript itself, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement. But given the specific nature of the announcement about the earnings call, the best classification is Call Transcript (CT) as it relates directly to the earnings call event.
2024-01-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an official communication from Rossari Biotech Limited to stock exchanges regarding the scheduling of an earnings conference call for Q3 FY24. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events. The document includes details about the date and time of the call, dial-in information, and a brief description of the company. It explicitly states that the earnings results for the quarter ended December 31, 2023, will be declared on January 20, 2024, and the call will follow on January 23, 2024. The document does not contain any actual financial data or results but is an announcement of the upcoming earnings call event. According to the classification rules, announcements of earnings calls or invitations to such calls are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this document is only an intimation or invitation to the earnings call, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about an event related to earnings but does not contain the earnings release or transcript itself. The document length is 4381 characters, which is relatively short and consistent with an announcement rather than a full report or transcript.
2024-01-16 English
Board Meeting — ROSSARI BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 20-Jan-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for t…
Regulatory Filings
2024-01-12 English
Board Meeting — Financial Results
Regulatory Filings Classification · 90% confidence The document text is mostly garbled or corrupted and does not contain any clear financial data, report titles, or regulatory references. The length is only 1965 characters, which is quite short and suggests it is not a full financial report. There is a digital signature noted, which often appears in regulatory filings or attestations. Given the lack of substantive content and the presence of a signature, this document is likely an officer certification or a regulatory attestation rather than a full report. According to the rules, such documents should be classified as Regulatory Filings (RNS).
2024-01-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate addressed to stock exchanges regarding Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018. It confirms dematerialisation of shares and cancellation of share certificates for the quarter ended December 31, 2023. The document is short (1407 characters) and serves as a regulatory compliance confirmation rather than a financial report or detailed filing. It does not contain financial statements or detailed analysis, nor is it an announcement of a report publication. It is primarily a regulatory compliance certificate submitted to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance confirmations and miscellaneous regulatory documents.
2024-01-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.